This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2010 by ChaingMai University.
Recruitment status was:  Recruiting
Information provided by:
ChaingMai University Identifier:
First received: July 16, 2010
Last updated: July 21, 2010
Last verified: June 2010
This is a randomized double blind placebo-controlled study that will assess the efficacy of Tamsulosin oral-controlled absorption system (OCAS) 0.4 mg in the conjunctive medical treatment of distal ureteral stones with a size of 4-10 mm compared to placebo in control group.

Condition Intervention Phase
Ureteral Calculi Drug: Tamsulosin Hydrochloride OCAS 0.4 mg Other: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study

Resource links provided by NLM:

Further study details as provided by ChaingMai University:

Primary Outcome Measures:
  • Stone expulsion rate and time. [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Number of diclofenac injection used [ Time Frame: 28 days ]
  • Rate of occurrence of adverse events [ Time Frame: 28 days ]

Estimated Enrollment: 120
Study Start Date: June 2010
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Other: Placebo
One tablet OD for a maximum of 28 days
Experimental: Tamsulosin Hydrochloride OCAS 0.4 mg Drug: Tamsulosin Hydrochloride OCAS 0.4 mg
One tablet OD for a maximum of 28 days

Detailed Description:
  • patient will be randomized to receive placebo or Tamsulosin OCAS 0.4 mg 1 tablet OD for a maximum of 28 days or until the ureteral stone is passed and sodium diclofenac 50 mg twice a day, for 10 days.
  • All patients will receive 75 mg sodium diclofenac via intramuscular on demand

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patient aged => 18 years.
  • Patients who have distal ureteral stones with a size of 4-10 mm
  • Written informed consent has been obtained.

Exclusion Criteria:

  • Patients with history of ureteral surgery
  • Patients with urinary tract infection
  • Patient with diabetes and peptic ulcer
  • Patient with renal dysfunction (elevated of serum creatinine level)
  • Patients with severe hydronephrosis
  • Patients with history of passing stones
  • Pregnancy
  • Patients who desire to withdraw from the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01167062

Contact: Bannakij Lojanapiwat, M.D. 66-53-945532

Maharat Nakhon Chiangmai Hospital Recruiting
Muang, Chiangmai, Thailand, 50200
Contact: Bannakij Lojanapiwat, M.D.    66-53-945532   
Principal Investigator: Bannakij Lojanapiwat, M.D.         
Sponsors and Collaborators
ChaingMai University
  More Information

Responsible Party: Bannakij Lojanapiwat M.D, Chiang Mai University Identifier: NCT01167062     History of Changes
Other Study ID Numbers: TAM040-0109
Study First Received: July 16, 2010
Last Updated: July 21, 2010

Additional relevant MeSH terms:
Ureteral Calculi
Pathological Conditions, Anatomical
Ureteral Diseases
Urologic Diseases
Urinary Calculi
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on September 25, 2017